PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.333
https://www.valueinhealthjournal.com/article/S1098-3015(19)32711-1/fulltext
Title :
PCN137 COST COMPARISON OF ADVERSE EVENTS AND TREATMENT ADMINISTRATION OF LURBINECTEDIN VERSUS INTRAVENOUS TOPOTECAN FOR RELAPSED SMALL CELL LUNG CANCER IN SPAIN AND THE UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32711-1&doi=10.1016/j.jval.2019.09.333
First page :
Section Title :
Open access? :
No
Section Order :
10271